Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Sees Large Decrease in Short Interest

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the target of a significant decrease in short interest in January. As of January 15th, there was short interest totaling 28,845 shares, a decrease of 28.4% from the December 31st total of 40,313 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 47,850 shares, the days-to-cover ratio is presently 0.6 days. Based on an average daily volume of 47,850 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the company’s stock are short sold.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research note on Tuesday, November 4th. Wall Street Zen raised shares of Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. Finally, Leerink Partners restated an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Nanobiotix has an average rating of “Hold” and a consensus price target of $11.00.

Nanobiotix Trading Down 4.1%

Shares of NASDAQ NBTX opened at $21.00 on Friday. The firm’s 50 day moving average price is $21.60 and its 200-day moving average price is $16.76. Nanobiotix has a 52-week low of $2.95 and a 52-week high of $30.35.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nanobiotix stock. Optiver Holding B.V. acquired a new position in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.